Tag: dermatology

Clinical Research: Phase 1 - Phase 4

The Pathogenesis of Acne and What It Means for Drug Developers

Acne — specifically acne vulgaris — is the most common skin disorder in the United States, affecting up to 50 million Americans each year. While many cases are restricted to mild manifestations during one’s teenage years, acne is a highly visible condition that can have a major impact on a patient’s quality of life. It’s a disorder with the potential...

Clinical Research: Phase 1 - Phase 4

Conventional Treatments for Atopic Dermatitis

While there is currently no cure for atopic dermatitis (AD) — commonly called eczema — this prevalent condition can often be well managed through conventional drug therapies. Current AD strategies used by dermatologists include symptom relief, patient/parent education, and the prevention of secondary complications. The “Gold Standard” for Mild to Moderate Atopic Dermatitis The most frequently used therapies...

Clinical Research: Phase 1 - Phase 4

Biologics in Psoriasis Treatment

Biologics have revolutionized psoriasis treatment over the last two decades. These targeted immunomodulatory therapies act directly on the cytokine pathways that are upregulated in psoriasis and other autoimmune diseases. Two major classes make up biologics in psoriasis treatment: tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors. TNF Inhibitors TNF inhibitors became the first available biologic...

Consulting

What Is Atopic Dermatitis?

Atopic dermatitis (AD), also known as atopic eczema, is a common skin disorder affecting millions of people worldwide. While many cases are mild, AD can take a significant financial and emotional toll on patients and their loved ones. What are the symptoms of atopic dermatitis? AD is characterized by skin barrier function abnormalities and skin...

Consulting

The Complicated Pathogenesis of Psoriasis

Psoriasis is an autoimmune disease that affects 7.5 million people in the United States and roughly 100 million worldwide. While its main manifestation is in unsightly, often irritating skin lesions, many patients also experience painful psoriatic arthritis. Additionally, psoriasis often comes with a wide range of other chronic conditions, including Type 2 diabetes, cardiovascular disease and...

Clinical Research: Phase 1 - Phase 4

Challenges and Solutions in Conducting Psoriasis Clinical Trials

Designing and conducting psoriasis clinical trials is tricky. After all, psoriasis is a highly variable group of conditions that produce a range of debilitating and often subjective symptoms. So how do researchers assess efficacy in novel psoriasis treatments? Read on for the answer. Considerations for Psoriasis Trials In clinical practice, broad global assessments are used...

Consulting

More Than Skin Deep: Beyond the Dermatological Manifestations of Psoriasis

Psoriasis is caused by dysregulated interactions of the innate and adaptive immune system in skin epithelium and connective tissue, including the activation and proliferation of T helper cells. As an autoimmune disorder causing widespread inflammation, it is unsurprising that psoriasis is associated with a number of non-dermatological conditions. Continued psoriasis research may give insight into the etiology...

Clinical Research: Phase 1 - Phase 4

Understanding Psoriasis

Psoriasis is a dermatological disorder that is often paired with underlying systemic disease and multiple comorbidities. While a common condition, its wide range of severity and causes, along with several clinical subtypes, make it challenging to treat. Global Impact of Psoriasis The World Health Organization estimates at least 100 million individuals globally live with psoriasis,...

Consulting

Therapeutic Revolution: A Webinar on the Fight Against Psoriasis

DURHAM, N.C., MARCH 27, 2017 — A therapeutic revolution is changing the lives of many afflicted with severe psoriasis. New treatments are breaking the cycle of patient “heartbreak” made famous in product advertising decades ago. Premier Research will explore these advances in a webinar on Wednesday, March 29. Dr. Howard Welgus, Executive Medical Director for Dermatology,...